ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates

Financial Performance - ARS Pharmaceuticals, Inc. reported a quarterly loss of $0.52 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.45, representing an earnings surprise of -15.56% [1] - The company posted revenues of $32.5 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 14.08%, compared to revenues of $2.07 million in the same quarter last year [2] - Over the last four quarters, ARS Pharmaceuticals has surpassed consensus revenue estimates three times [2] Stock Performance - ARS Pharmaceuticals shares have declined approximately 16.1% since the beginning of the year, while the S&P 500 has gained 14.4% [3] - The current Zacks Rank for ARS Pharmaceuticals is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.35 on revenues of $31.06 million, and for the current fiscal year, it is -$1.66 on revenues of $81.76 million [7] - The earnings outlook and estimate revisions trend for ARS Pharmaceuticals have been unfavorable leading up to the earnings release [6] Industry Context - The Medical - Drugs industry, to which ARS Pharmaceuticals belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]